



Responding to Federal and State Investigations and Enforcement Actions

Michael K. Loucks

February 19, 2013

Skadden

Beijing
Boston
Brussels
Chicago
Frankfurt
Hong Kong

Houston
London
Los Angeles
Moscow
Munich
New York

Palo Alto
Paris
São Paulo
Shanghai
Singapore
Sydney

Tokyo
Toronto
Vienna
Washington, D.C.
Wilmington

- Beijing
- Boston
- Brussels
- Chicago
- Frankfurt
- Hong Kong
- Houston
- London
- Los Angeles
- Moscow
- Munich
- New York
- Palo Alto
- Paris
- São Paulo
- Shanghai
- Singapore
- Sydney
- Tokyo
- Toronto
- Vienna
- Washington, D.C.
- Wilmington

Name of Co.	Year	Total Recovery	Criminal Fine	Date of Alleged Conduct	Filing or Initiation Date (or reference in settlement agreement)	Share to Whistleblower
AstraZeneca Pharms.	2009	\$2,600,000			6/20/2006	\$10,787,392
Aventis Pharm. Inc., subsidiary of Sanofi-Aventis US LLC	2009	\$95,500,000		1995-2000		
Eli Lilly	2009	\$1,415,000,000	\$515,000,000	1999-2003	2/19/2003 6/3/2006 12/19/2006 5/3/2007	\$78,870,877
Mylan Pharms. and UDL Labs.	2009	\$118,000,000			3/16/2004	\$10,787,392

Ortho McNeil Pharm.	2009	\$3,400,000			6/20/2006	\$10,787,392
Pfizer, Inc. through its subsidiary Pharmacia & Upjohn Co.	2009	\$2,300,000,000	\$1,300,000		8/13/2004 10/24/2005 11/21/2005 10/7/2005 9/1/2006 2/16/2007 6/15/2007 9/17/2007 10/1/2007 8/1/2008	\$51,500,999 \$2,743,637 \$2,354,582 \$7,431,505 \$29,013,420 \$9,321,369	
Abbott Labs. and its subsidiary Kos Pharms.	2010	\$41,360,000	\$3,360,000	2002-2004	3/19/2004, 7/12/2004		Still undecided by settlement agreement
Abbott Labs., Inc.	2010	\$126,500,000			3/17/2006		\$88,400,000 (all Ven-a-Care cases)
Allergan Inc.	2010	\$600,000,000	\$375,000,000	2001-2008	6/5/07 10/26/09 , 2/22/08		\$37,827,000

Alpharma Inc.	2010	\$42,500,000		2000-2008	9/18/2006	\$5,332,771
AstraZeneca LP and AstraZeneca Pharms. LP	2010	\$520,000,000		2001-2006	9/8/2006	\$45,286,051
B. Braun Medical Inc., subsidiary of B. Braun Melsungen AG	2010	\$14,744,000			9/6/2002	\$2,506,480
Cardinal Health 100, Inc.	2010	\$5,500,000		1997-2000	unknown, settlement 7/6/2010	No whistleblower
Dey Inc., Dey Pharma L.P., and Dey L.P. Inc.	2010	\$280,000,000			8/24/2006	\$67,200,000
Eisai Inc.	2010	\$11,000,000			7/16/2004	\$1,141,515
Elan Corp. PLC and its subsidiary Elan Pharms. Inc.	2010	\$203,000,000	\$97,050,266		7/16/2004	\$10,708,466

Eon Labs Inc.	2010	\$3,500,000		1999-2008	8/29/2002	\$522,000
Ethex Corp., subsidiary of KV Pharm.	2010	\$27,568,921	\$23,437,382	2007-2008	3/2/2010	No whistleblower
Forest Pharms. Inc.	2010	\$313,000,000	\$150,000,000	~1997-2003	3/4/2003, 1/28/2005, 8/29/2002	\$10,948,312 \$3,664,758
GeneScience Pharm. Co. and Jin, Lei	2010	\$7,500,000	\$4,500,000	2004-2007	9/19/2007	No whistleblower
Novartis Pharms. Corp.	2010	\$422,500,000	\$185,000,000		7/25/2003 4/16/2004 4/18/2006 6/3/2008	\$20,202,809 \$ 2,511,611 \$2,200,981 \$759,634
Novartis Vaccines & Diagnostics Inc. and Novartis Pharms. Corp.	2010	\$72,500,000		2001-2006	10/6/2006	\$7,824,668

Ortho-McNeil Pharm. LLC and Ortho-McNeil-Janssen Pharms. Inc.	2010	\$81,510,000	\$6,140,000		8/5/2003 8/30/2004	\$9,123,927
Roxane Labs. Inc., n/k/a Boehringer Ingelheim Roxane Inc.	2010	\$280,000,000			2/9/2007	\$67,200,000	
SB Pharmco Puerto Rico Inc., a subsidiary of GlaxoSmithKline PLC	2010	\$750,000,000	\$150,000,000	2000-2005	2/27/2004	\$96,016,800	
Schwarz Pharma Inc.	2010	\$22,000,000			2/5/2008 8/29/2002	\$1,836,575	

EMD Serono Inc., Merck Serono S.A., and Ares Trading S.A.	2011	\$44,300,000		2002-2009	12/29/2005	\$5,190,000	...
KV Pharmaceutical Company	2011	\$17,000,000			8/29/2002	\$1,523,804	
Marc Hermelin	2011	\$1,900,000	\$1,900,000	2006-2008	3/10/2011	Agreement still not reached	
Merck, Sharp & Dohme	2011	\$950,000,000	\$321,636,000	1999-2004	11/22/2011	No whistleblower	
Novo Nordisk Inc.	2011	\$25,000,000			10/30/2008	\$3,578,107	
Pfizer, Inc.	2011	\$14,500,000			2/2/2006	\$3,282,019	
UCB Inc., subsidiary of USC SA	2011	\$34,000,000	\$8,628,000		6/14/2007 10/3/2008	\$2,856,819	

Abbott Laboratories, Inc.	2012	\$1,500,000,000	\$700,000,000	1998-2006	10/31/2007 12/8/2008 6/15/2009 1/21/2010	\$84,127,704
Cypress Pharmaceutical Inc., subsidiary Hawthorn Pharmaceuticals Inc. and CEO, Max Draughn	2012	\$2,800,000		2003-2009	4/14/2008	\$300,000
Dava Pharmaceuticals Inc.	2012	\$11,000,000		2005-2009	2/19/2010	\$1,650,000
GE Healthcare Inc.	2012	\$30,000,000		2000-2003	11/29/2006	\$5.1 million
GlaxoSmithKline LLC	2012	\$3,000,000,000	\$956,814,400	1998-2007 (varying by drug)	4/7/2003 Consolidated 3/7/2011	Amount undecided as of settlement
McKesson Corporation	2012	\$190,000,000			11/30/2006	No whistleblower

- Beijing
- Boston
- Brussels
- Chicago
- Frankfurt
- Hong Kong
- Houston
- London
- Los Angeles
- Moscow
- Munich
- New York
- Palo Alto
- Paris
- São Paulo
- Shanghai
- Singapore
- Sydney
- Tokyo
- Toronto
- Vienna
- Washington, D.C.
- Wilmington

Americas



Europe



Asia/Pacific

